匯豐研究:首予百威亞太(1876.HK)“買入”評級 目標價33港元
匯豐環球研究首予百威亞太(01876.HK)評級“買入”,目標價33港元,指啤酒於亞太市場發展迅速,相信主要受惠於市場消費者眾多,及消費者偏好高端產品等有利因素所帶動。該行料百威亞太於未成熟之亞太西部市場發展較快,料今年收入可增長1.1%,2020年及2021年增長則可達8.6%及7.3%。於較成熟的亞太東部市場發展則稍慢,料今年全年相關地區收入倒退5.4%,2020年及2021年則分別增長6.1%及5.1%。
該行並預計,在百威亞太更好管控成本的情況下,純利於2019年至2021年複合增長率可達15.5%,至2021年達到14.8億美元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.